Background
==========

T cells are considered to be pivotal cells in the pathogenesis of rheumatoid arthritis (RA) and therefore represent a potential target for treatment. The novel disease-modifying antirheumatic drug (DMARD) leflunomide inhibits pyrimidine biosynthesis. T cells are especially susceptible to inhibition of this enzyme due to increased demand for pyrimidines after activation, together with the absence of a salvage pathway.

Objective
=========

We investigated the effects of leflunomide on cytokine profiles *in vivo* and *in vitro* to provide more insight into the mechanism of action of leflunomide in RA.

Methods
=======

Serum samples from 100 RA patients, treated with either leflunomide (*n* = 50) or methotrexate (*n* = 50), were collected at baseline, after 12 weeks and after 1 year of treatment. In these samples, serum levels of interleukin-6 (IL-6) and interferon gamma (IFN-γ) were determined by ELISA. The effects of the active metabolite of leflunomide (A77-1726; 0--200 μM) on IL-6 and IFN-γ production by peripheral blood mononuclear cells (PBMCs) from healthy volunteers (*n* = 6) and RA patients (*n* = 3) were studied by ELISA after activation (with phytohemagglutinin, lipopolysaccharide, and αCD3/αCD28) by ELISA. In addition, monocytes and lymphocytes were isolated from two healthy volunteers by density-gradient centrifugation methods, and effects of A77-1726 on IL-6 production after activation (with phytohemagglutinin or lipopolysaccharide) were measured by ELISA and PCR. Effects on cell proliferation (^3^H-thymidine incorporation), were measured as well.

Results
=======

Serum levels of IFN-γ were significantly reduced after leflunomide treatment (baseline 43 pg/ml ± 10 \[mean ± SEM\]; 1 year 29 ± 7 \[*P* = 0.015\]), whereas we did not observe a change in IL-6 concentrations in serum (baseline 158 ± 41, 4 months 151 ± 48). In contrast, both IFN-γ and IL-6 serum levels were significantly reduced after methotrexate treatment. Consistent with these data, *in vitro* experiments revealed a dose-dependent inhibition of IFN-γ production by activated PBMCs in both healthy volunteers and RA patients in the presence of A77-1726, without a clear-cut effect on IL-6 production. IL-6 production by monocytes was not inhibited (measured by ELISA and PCR). Production of IFN-γ by lymphocytes was inhibited by A77-1726.

Conclusion
==========

The results presented here show inhibition of IFN-γ production by leflunomide without a clear-cut effect on IL-6 production. This differential effect supports the hypothesis that leflunomide preferentially affects activated T cells. The effects on T cells could be explained by both DHODH inhibition and effects on signal transduction pathways.
